A
Apogee Therapeutics, Inc. (APGE)
NGM – Real Time Price. Currency in USD
82.93
-1.67 (-1.97%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
82.93
-1.67 (-1.97%)
At close: May 12, 2026, 4:00 PM EDT
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Rα for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
| Name | Position |
|---|---|
| Dr. Carl Linden Dambkowski M.D. | Chief Medical Officer |
| Dr. Drew Badger Ph.D. | Senior VP and Head of Regulatory Affairs & Toxicology |
| Dr. Michael Thomas Henderson M.D. | CEO & Director |
| Dr. Rebecca Dabora Ph.D. | Chief Development Officer |
| Mr. Matthew Batters J.D. | Chief Legal Officer & Corporate Secretary |
| Ms. Emily Cox | SVP & Head of People |
| Ms. Jane Pritchett V. Henderson | Chief Financial Officer |
| Ms. Monica Forbes | Senior Vice President of Finance |
| Ms. Noel Kurdi | Vice President of Investor Relations |
| Ms. Wendy Aspden-Curran | Senior Vice President of Clinical Operations |
| Date | Type | Document |
|---|---|---|
| 2026-05-11 | 8-K | apge-20260511.htm |
| 2026-04-24 | DEFA14A | apge_defa_14a_2026.htm |
| 2026-04-24 | ARS | apge_ars_2026.pdf |
| 2026-03-25 | 8-K | tm269761d1_8k.htm |
| 2026-03-23 | 8-K | tm269553d1_8k.htm |
| 2026-03-02 | S-8 | tm267328d1_s8.htm |
| 2026-03-02 | 8-K | apge-20260302.htm |
| 2026-03-02 | 10-K | apge-20251231.htm |
| 2026-01-06 | 8-K | tm261950d1_8k.htm |
| 2025-11-10 | 8-K | apge-20251110.htm |